Big Money Are Crazy For CONCERT PHARMACEUTICALS (NASDAQ:CNCE), Sentiment at 1.64

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Corporate Logo


“Big money sentiment for CONCERT PHARMACEUTICALS (NASDAQ:CNCE) in 2018 Q2 increased to 1.64, filings reveal. So its up 0.27, from 2018Q1’s 1.37. 69 funds opened new and increased positions, while 42 reduced and sold equity positions in CONCERT PHARMACEUTICALS so the sentiment has increased. Funds own 16.41 million shares, down from 16.64 million shares in 2018Q1. Funds holding CONCERT PHARMACEUTICALS in top 10 changed to 0 from 1 for a decrease of 1. 18 Investors Sold All; 24 Reduced Holdings; 45 increased stakes while 24 funds bought stakes.


Bvf Inc Il owns 1.82 million shares in CONCERT PHARMACEUTICALS as of 2018 Q2. CONCERT PHARMACEUTICALS’s shareholder Senzar Asset Management Llc owns 29,821 shares as of 2018 Q2. Further, Ingalls & Snyder Llc reported 1.34 million shares in CONCERT PHARMACEUTICALS equivalent to 1.04% of its fund’s portfolio. The New York-based fund Knott David M have invested about 0.33% of the institutional investor’s stock portfolio in CONCERT PHARMACEUTICALS. The United Kingdom-based fund Gsa Capital Partners Llp holds 123,700 shares or 0.1% of their fund’s portfolio.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company.The firm is valued at $293.34 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders.Currently it has negative earnings. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

CNCE touched $12.52 during the last trading session after $0.05 change.Concert Pharmaceuticals, Inc. has 308,863 shares volume, 41.25% up from normal. CNCE is downtrending and has moved 5.89% since December 8, 2017. The stock underperformed the S&P 500 by 21.51%.

Earnings report for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) is awaited on March, 7., Faxor reports. EPS of $-0.74 is 184.62 % down from 2017’s $-0.26 EPS. After $-0.74 EPS was announced previous quarter, analysts now see EPS growth of 0.00 % for Concert Pharmaceuticals, Inc..

Assetmark holds 0% or 131 shs. New York-based Tiaa Cref Investment Lc has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Financial Bank Of New York Mellon holds 0% or 170,848 shs in its capital. Clarivest Asset Mgmt Limited Liability Company holds 0.03% or 105,942 shs. Element Capital Mgmt reported 29,392 shs. Connor Clark Lunn Inv Mngmt reported 413,122 shs. Spark Inv Limited Liability Corporation holds 0.1% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 97,200 shs. State Street Corporation reported 415,318 shs or 0% of all its holdings. Switzerland-based Credit Suisse Ag has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Renaissance Techs Lc owns 494,200 shs or 0.01% of their US capital. Citadel Ltd Liability has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Moreover, Cap Fund Mngmt has 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 14,500 shs. Alps has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Los Angeles Capital Mngmt Equity holds 17,910 shs or 0% of its capital. Northern Tru Corp has invested 0% of its capital in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE).

Concert Pharmaceuticals, Inc. had 1 sale and 3 insider purchases since July 9, 2018. This’s net activity of $53,106. The insider Stuart Nancy sold 31,418 shs worth $561,587. $591,262 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shs were bought by ALDRICH RICHARD.

For more Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) news posted recently go to:,,, or The titles are as follows: “Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018 – Business Wire” posted on February 21, 2018, “Concert Pharma continues CTP-543 data-stoked selloff, down 5% – Seeking Alpha” on November 14, 2018, “48 Stocks Moving In Friday’s Mid-Day Session – Stockhouse” with a publish date: November 16, 2018, “Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata – Business Wire” and the last “Concert Pharmaceuticals: Thoughts Going Into 2018 – Seeking Alpha” with publication date: December 04, 2017.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.